Health Care

Lilly Antibody Combo Therapy Reduced Viral Levels, Study Says

Lilly Antibody Combo Therapy Reduced Viral Levels, Study Says”

While vaccines work by triggering the body to develop neutralizing antibodies, the Lilly drug gives the virus-fighting molecules directly to a person, saving the time before vaccine's effect kicks in and potentially helping people whose immune system may not be strong enough to launch an adequate response to vaccines, such as nursing home residents.

"We are exceptionally pleased with these positive results, which showed bamlanivimab was able to help prevent COVID-19, substantially reducing symptomatic disease among nursing home residents, some of the most vulnerable members of our society", said Daniel Skovronsky, the company's chief scientific officer, using the trade name for the antibody.

"I see the monoclonal antibody treatment as our only key option for our highest risk patients into the summer until we get that very comprehensive vaccination complete", said Dr. James Lederer, chief medical officer of Berkshire Health Systems, who has provided the treatment to MA patients. In the 41 residents who had already tested positive, none died after receiving the drug compared to 4 deaths in the placebo group.

Among the almost 300 residents who did not have COVID-19, four later got the disease and died.

A drug developed by Eli Lilly dramatically reduced the risk of developing symptomatic COVID-19 among nursing home residents, the company said.

It is a randomised, double-blind, placebo-controlled trial to analyse the efficacy and safety of bamlanivimab 4200mg versus placebo in preventing Covid-19 in skilled nursing and assisted living facility (nursing home) residents and staff. It was the first monoclonal antibody therapy for COVID-19 to enter human testing in the United States and was granted the EUA based on data from the Phase II Blaze-1 study. In the United States, they account for less than 1% of the population, but almost 40% of deaths from COVID-19.

More news: NBC Sports Network to shut down at end of 2021

"These data provide important additional clinical evidence regarding the use of bamlanivimab to fight COVID-19 and strengthen our conviction that monoclonal antibodies such as bamlanivimab can play a critical role in turning the tide of this pandemic". Patients and physicians can visit covid.infusioncenter.org.

BLAZE-2 is a first-of-its-kind COVID-19 trial created to evaluate this vulnerable population by addressing the challenging aspects of running a clinical trial in long-term care facilities, which normally do not conduct clinical trials.

For more information about the use of bamlanivimab, contact Lilly's 24-hour support line at 1-855-LillyC19 (1-855-545-5921).

"These results exceed our expectations, demonstrating that this class of treatments can be used to both prevent and treat disease", said Nick Cammack, Covid-19 Therapeutics accelerator lead at Britain's Wellcome charity.

According to Eleanor Riley, professor of immunology at the University of Edinburgh, this type of synthetic antibody treatment could be a complete vaccine. Serious adverse events were reported at a similar frequency in the bamlanivimab and placebo groups.



Like this

loading...
loading...

Latest


23 January 2021
Syria: Two children among family killed by Israeli strikes, says state media
The Israeli Defense Forces (IDF) announced Friday that its troops downed a drone that entered Israel's airspace from Lebanon. Israel's military said on Friday it downed a drone that crossed from Lebanon and would continue to protect its sovereignty.

23 January 2021
Brooks’ milestone helps patchwork Maple Leafs pick up win over Oilers
Friday's opening 20 minutes weren't almost as tight-checking as Wednesday's chess match, with a couple of chances at either end. The Maple Leafs will head west for a pair of road games against both the Calgary Flames and Oilers.

23 January 2021
New UK variant of coronavirus may be more deadly, says Boris Johnson
Based on preliminary data briefing by scientists at the New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG), Mr. The total number of people in the country who have died within 28 days of a positive test now stands at 95,981.

23 January 2021
Pfizer offers 40 mn Covid shots to poorer countries at cost
The deal is a boost to the global program known as COVAX, as wealthy nations have snapped up most of the millions of coming shots. Seth Berkley, chief executive officer (CEO) of Gavi, the Vaccine Alliance, which leads COVAX procurement and delivery.

23 January 2021
This Dog Waited 6 Days Outside Hospital For Owner To Return
After a brief search, Senturk's family finally located her sitting outside the entrance of the hospital. "She's very used to me. Boncuk's unwavering loyalty follows several stories of dogs waiting long periods of time to be reunited with their owners.

23 January 2021
The Colts need a starting QB following Philip Rivers’ retirement
Rivers finishes his career having thrown for 63,440 yards and 421 touchdowns. "I can sit here and say, 'I can still throw it". He thanked officials for "putting up with all my fussing". "As my playing career comes to an end, the next chapter begins".

23 January 2021
Qualcomm Snapdragon 888 announced with integrated 5G
The modem also supports 5G carrier aggregation, global multi-SIM, standalone, non-standalone, and Dynamic Spectrum Sharing. The Qualcomm Snapdragon 888 is the chip that'll power your next flagship smartphone (like the Galaxy S21 ).

23 January 2021
Wayne Rooney thinks Manchester United will win the Premier League
There has been much talk of the resurgence of Luke Shaw at left back recently but his fellow full back is playing just as well at the moment.

23 January 2021
WHO, Pfizer strike Covax deal for 40 million Covid-19 vaccine doses
The WHO listed the vaccine for emergency use on December 31: saying it met its must-have criteria for safety and efficacy. Nine of the 10 people had a history of allergies and five of them had previously experienced an anaphylactic reaction.

23 January 2021
Arsenal's Arteta shifts focus to new recruits after moving players on
One of the main objectives was to make some decisions of how we're going to offset that". So if we can, we will do it, and if we can't, we'll just keep going with what we have".